Meeting
2016 ASCO Annual Meeting
Quality of life (QOL) to predict overall survival (OS) in women with platinum-resistant ovarian cancer (PROC).
Authors
Felicia Roncolato
St George Hospital, Sydney, Australia
Felicia Roncolato , Emma Gibbs , Chee Lee , Lucy Claire Davies , Val Gebski , Michael Friedlander , Felix Hilpert , Lari B. Wenzel , Martin R. Stockler , Madeleine Trudy King , Eric Pujade-Lauraine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT00976911
Citation
J Clin Oncol 34, 2016 (suppl; abstr 5575)
DOI
10.1200/JCO.2016.34.15_suppl.5575
Abstract #
5575
Poster Bd #
398
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Bevacizumab (BEV) with or after chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (PROC): Exploratory analyses of the AURELIA trial.
First Author: Aristotelis Bamias
Poster
2015 ASCO Annual Meeting
Development and validation of a prognostic nomogram to predict overall survival (OS) in platinum-resistant ovarian cancer (PROC): An AURELIA substudy.
First Author: Chee Lee
Poster
2022 ASCO Annual Meeting
Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer.
First Author: Gordon Taylor Moffat
Poster
2013 ASCO Annual Meeting
Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC).
First Author: Martin R. Stockler